Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 67

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 67
---
 our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products 37 approved for marketing. If we are unable to obtain insurance at an acceptable cost or otherwise protect against potential product liability claims, we will be exposed to significant liabilities, which may materially and adversely affect our business and financial position. If we are sued for any injury allegedly caused by our Program Products, our liability could exceed our total assets and our ability to pay the liability. A product liability claim or series of claims brought against us would decrease our cash and could cause our stock price to fall. Our insurance policies are expensive and protect us only from some business risks, which will leave us exposed to significant uninsured liabilities. We carry insurance for most categories of risk that our business may encounter; however, we may not have adequate levels of coverage. We currently maintain general liability, property, workers’ compensation, clinical study, products liability and directors’ and officers’ insurance, along with an umbrella policy. We may not be able to maintain existing insurance at current or adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations. We have no current plans to pay dividends on our shares of common stock. We do not anticipate paying any cash dividends in the foreseeable future. If we incur indebtedness in the future to fund our future growth, our ability to pay dividends may be further restricted by the terms of such indebtedness. Loss of Emerging Grown Company Status We are no longer an emerging growth company (“EGC”) as defined in the Jumpstart Our Business Startup Act of 2012, as amended. As a result, we are now subject to additional regulatory and compliance obligations, which may increase our costs, divert management’s attention, and adversely affect our financial condition. These obligations include: •Enhanced disclosures: We must provide expanded executive compensation disclosures and comply with new or revised accounting standards on the same timeline as non -EGCpublic companies. •Reduced flexibility: We can no longer use EGC exemptions for test -the -waterscommunications or scaled executive compensation disclosures. Our transition from EGC status became effective on December 31, 2024, as we exceeded the five -yearanniversary of our initial public offering. However, we continue to qualify as a smaller reporting company under SEC rules and as defined in the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which permits certain scaled disclosures but does not alleviate all obligations triggered by